# HIFP — GTM Tier Strategy v0.2

**Purpose.** Ground the 2026-09-08 Brandon-proposed GTM tier structure (Ledger §3.42) in TAM/SAM math, per-tier value propositions, PMPM public-comp defensibility, and a concrete viral-loop reading, so the trio has a defensible POV to ratify (or reshape) Friday 2026-09-11. This memo is the analytical spine for POV v4 § GTM, Product Design v4, Business Plan v4 revenue model, Segment Messaging v4 sub-segment matrix, Investor Deck v4, and Q&A v4.

**Date.** 2026-09-08
**Owner.** Brandon (proposal) → Trio (ratification Friday 2026-09-11)
**Version.** v0.4 — pre-ratification working draft (v0.3 → v0.4 applies Brandon read-through corrections from POV v4 draft-01 review: fixes premium-case percentage arithmetic error · reframes T3 pricing frame from "80% value / 40% price" contradiction to honest "60–70% depth / ~60% PMPM" · restructures §4 revenue mix into three consistently-computed cases with methodology note · references POV v4 §12.7 wearable-longevity competitive threat + §12.8 Sindhu IP-assignment risk added downstream)
**Status.** Ledger §3.42 `[!]` — do NOT propagate to v3.x artifacts or v4 kit until trio ratifies.
**Companion.** [[HIFP-open-items-ledger-v0.1]] §3.42 · [[HIFP-next-meeting-agenda-2026-09-11]] Block 3 · [[HIFP-pivot-log-v0.1]] §2.6 (Monday Concierge reshape — this memo partially re-opens) · [[HIFP-segment-messaging-v0.1]] (queued for v4 rewrite)

---

## Executive summary

**T1 alone is arithmetically viable but structurally fragile. T2s exist for smoothness (T2a) and platform-multiple story (T2b). T3 exists to capture marketing leakage without diverting founder attention.**

Four claims this memo defends:

1. **Employer-only GTM hits Series-B-viable ARR under near-perfect execution and produces a story investors discount** — concentration risk, sales-cycle lumpiness, and "benefit-add" positioning cap the valuation multiple even when the arithmetic works.
2. **T2a Concierge practices are a smoothness lane, not a volume lane** — ~90-day sales cycles fill the gaps between 12–18-month employer closes and provide brand credibility with the top-quartile clinician network that HIFP's clinical bar requires.
3. **T2b "partner-channel D2C with viral bump" is a three-loop stack, not one viral engine** — primary engine is Consumer-Wellness Partnership channels (Function/Neko/Aura-shape rev-share), amplified by family-attach (Loop A, T1 mechanic) and practice-referral (Loop B, T2a mechanic). The honest label is "channel with viral characteristics."
4. **T3 Employer overflow (wider employer segment, inbound-only, lower-touch) is not a lane — it is a leak-capture mechanic** — HIFP's T1 marketing + benefit-consultant collateral + public content will naturally attract inbound from adjacent-shape employers (fully-insured F500, non-long-term-equity F1000, mid-market self-funded). Ignoring this inbound leaves 5–10% of ARR on the ground for zero incremental founder attention.

**Recommended 3-year target mix (three consistently-computed cases per v0.4 correction):** Downside (all lanes low-end PMPM) **~$40M ARR** · Base (all lanes midpoint PMPM) **~$57M ARR** · Premium (aggressive accounts × high-end PMPM) **~$142M ARR**. See §5 for methodology note + full lane breakdown; Series C valuation range **$3.5–5.7B** on premium. T2b carries ≥50% of the *user-count* story that shapes Series B/C multiples across all cases.

**Design principle for tier allocation:** T1/T2a/T2b consume scarce founder + eng attention and require active GTM motion; T3 consumes inbound-processing capacity only and MUST be self-serve or inside-sales-only. If T3 ever requires outbound motion, we kill it.

---

## §0 · Aggregate employer TAM at play (T1 + T3 combined)

The Brandon-articulated "marketing/messaging leakage" insight requires that we size the *combined* T1 + T3 employer opportunity, not just T1 in isolation. HIFP's brand + benefit-consultant collateral + T1 case studies produce awareness across the full addressable employer universe; the sizing table reflects what that reach actually maps to.

| Layer | Employer count | Covered lives | HIFP GTM disposition |
|---|---|---|---|
| **All US private-sector employers with 1+ employees** | ~6M | ~150M | Reference only; not addressable |
| **US employers 100+ employees (benefits-decision-maker threshold)** | ~110,000 | ~135M | Addressable universe |
| **Self-funded employers (all sizes)** | ~4,500+ (KFF 2024) | ~100M | T1 + T3 addressable |
| **T1 hyper-focus: self-funded × F500-shape long-term-equity comp** | ~500–1,000 | ~15–25M | Active outbound + benefit-consultant motion |
| **T3 addressable adjacent (broader employer leakage capture)** | ~15,000 (excluding T1) | ~90M (excluding T1) | Inbound-only; self-serve or inside-sales |
| **Combined T1 + T3 addressable universe** | **~16,000 employers** | **~115M covered lives** | Total employer-side reach |
| Serviceable T1 in 3-year window | 100–300 | 3–8M | Active |
| Serviceable T3 via inbound in 3-year window | 100–500 inquiries | ~1–4M | Inbound-elastic |
| Landable T1 in 3-year window (base case) | 30 employers | ~600K | Base case |
| Landable T3 in 3-year window (base case) | 20 employers | ~160K | Base case |
| **Combined landable Y3 (base case)** | **~50 employers** | **~760K covered lives** | ~$34M combined employer ARR |

**Reading of the aggregate.** HIFP's benefit-consultant relationships, published thought-leadership, and T1 case studies expose the brand to ~16K addressable employers covering ~115M lives — 4–6× the reach of the T1 hyper-focus band alone. **T3's leak-capture doctrine converts a fraction of that broader reach into revenue at essentially zero incremental outbound cost.** The doctrine is not "we grow into T3 later"; it is "we don't leave 5–10% of ARR on the ground while running T1."

---

## §1 · Why T1-only is insufficient

### 1.1 · T1 sizing — self-funded employers with long-term-equity hook

| Layer | Count | Covered lives | Basis |
|---|---|---|---|
| All US self-funded private employers | ~4,500+ (KFF 2024) | ~100M | KFF ESHBS |
| Self-funded × F500-shape long-term-equity comp (Salesforce-shape) | ~500–1,000 | ~15–25M | Estimate: F500 tech + F1000 finance + F1000 biotech/pharma with material RSU/stock comp |
| **Serviceable in 3-year window** | **100–300** | **3–8M** | Estimate: founder network + partner-channel reach + realistic broker/consultant introductions |
| **Landable in 3-year window** | **20–40** | **400K–1M** | 15–25% penetration of serviceable pipeline is aggressive-but-plausible for a first-time enterprise seller |

### 1.2 · T1 revenue arithmetic

Per-life economic value anchor: **$3–6 PMPM** for a personal-financial-planning benefit tied to health data (see Appendix B for PMPM public-comp pressure-test). Use **$4 PMPM = $48/life/year** as base-case; **$6 PMPM = $72/life/year** as premium tier (long-term-care-integrated).

**Base-case 3-year T1 ARR (30 employers × 20K avg lives × $48):** **~$29M**
**Premium-case 3-year T1 ARR (40 employers × 25K avg lives × $60):** **~$60M** (see Appendix A)

### 1.3 · Why T1-only fails as sole GTM

Four structural problems, each independently sufficient:

**A. Concentration risk suppresses valuation multiple.** With 20–40 T1 customers by Y3, top-5 concentration is typically 45–65% of ARR. VCs discount this heavily at Series B — a $30M ARR business with top-5 concentration of 55% trades closer to $200M valuation than the $400–500M that a diversified $30M ARR SaaS commands. **The multiple penalty is on the order of $150–300M of Series B pre-money.**

**B. Sales-cycle lumpiness kills quarterly predictability.** Self-funded-employer benefit-adds have documented 12–18-month procurement cycles (benefit consultant intro → HR eval → CFO sign-off → BOD approval → open-enrollment integration). One slipped procurement quarter = missed year. Investors punish this in growth-stage pricing far more than in seed-stage sentiment.

**C. Growth-rate ceiling from enterprise physics.** After Y2, T1-only growth caps at ~2× annually because you cannot compress the 12–18-month sales cycle by throwing money at it — every landed employer requires bespoke integration, benefits-consultant handshake, and open-enrollment timing. The "300% YoY growth" Series-B pitch is physically unavailable to a T1-only motion.

**D. "Benefit-add" positioning ceiling on the story.** "We are an employer-benefit company" is a smaller story than "consumer-primary platform with employer channel." The former is priced against Alight/HealthEquity/Livongo (10–15× ARR at maturity); the latter is priced against Robinhood/Wealthfront/Personal Capital (25–40× ARR at growth, before compression). Even flawless T1 execution caps the terminal multiple.

**Consequence.** T1-only GTM produces a $30M-ARR Series B story at $200–300M pre-money, which does not clear the founder-return math for a $2M SAFE at $15M cap taken pre-Series-A. **T2s + T3 are not commercial optionality — they are structural necessities for the funding architecture Brandon has locked.**

### 1.4 · T1 value proposition

**Buyer:** HR + Benefits + CFO at self-funded employer with long-term-equity comp mix.

**Value promised to the buyer:**
- **Talent retention lift on RSU-vesting curve.** Employees who understand and optimize their long-term equity + coverage + household financial trajectory stay 6–18 months longer through vesting cliffs — measurable in HRIS retention-at-3-year metric. Anchor: Salesforce H&LS ratified financial-wellness benefit tied to reduction in early-vest churn (Sindhu + Fatima network intel).
- **Executive-perk-tier for C-suite.** Integrated executive-health + financial-planning surface for top 50–200 employees — differentiated recruiting mechanic vs comp-only offers. Analog: Executive Health Group / Cleveland Clinic exec physicals + Fidelity personal-CFO for founders / execs.
- **Productivity + healthcare cost impact.** Financial-stress-related productivity losses are ~$3,500/employee/year (SHRM 2024); healthcare cost impact of untreated financial stress ~$400/employee/year (Mercer). HIFP claims 15–25% reduction of both via biomarker-informed planning quality. Measurable in HRIS + benefits-utilization data.
- **Differentiated benefit no competitor offers.** No other benefit vendor combines biomarker + financial-planning + household aggregation in one authenticated surface. Alight/Fidelity offer financial wellness; Livongo/Teladoc offer clinical; none combine.

**Value promised to the covered employee (secondary buyer influence):**
- "See your household's real financial trajectory, not a rosy or a scary one" — Plan-Delta framing
- Household aggregation (Loop A family-attach) with per-source revocation and Apple-privacy-policy standard consent
- Coverage Navigator surface with three-tier (federal/state/zip) regulatory awareness

**Anti-value (what HIFP will NOT do for the buyer):**
- HIFP does not clinically intervene, adjudicate coverage, provide advice as a fiduciary, or become a Coverage Navigator on the employer's behalf. Boundary-Integrity spec applies.
- HIFP does not share employee financial or health data with the employer at individual granularity. Data-scope architecture is non-negotiable.

---

## §2 · Why T2a Concierge practices are the smoothness lane

### 2.1 · T2a sizing

| Layer | Count | Patient lives | Basis |
|---|---|---|---|
| US concierge / DPC practices | ~1,500 | ~5–8M | MDVIP ~450K (1,300–1,400 physicians, Source Log r2 VERIFIED) + One Medical ~900K + independent DPC ~4–6M |
| Serviceable in 3-year window | 200–400 practices | ~1.5–3M | Estimate: MDVIP + selected One Medical geographies + independent DPC via clinical-network referral |
| **Landable base case Y3** | **30 practices** | **~75K patients** | 2,500 avg patient panel per landed practice; 10–15% penetration of serviceable |
| **Landable premium case Y3** | **75 practices** | **~300K patients** | Aggressive; 4,000 avg patient panel; ~25% penetration |

### 2.2 · T2a revenue arithmetic

Practice pays higher PMPM than employer because value is patient-retention-tied (concierge/DPC business model already prices at $1,500–5,000/patient/year). Anchor: **$8–12 PMPM = $96–144/patient/year** (see Appendix B for concierge tech-add-on comp anchors). Use **$120/patient/year** base-case.

**Base-case 3-year T2a ARR (30 practices × 2,500 avg patients × $120):** **~$9M** (round to $10M in mix table)
**Premium-case 3-year T2a ARR (75 practices × 4,000 avg patients × $120):** **~$36M** (see Appendix A)

But headline ARR is not why T2a exists. Three structural roles:

**A. Revenue smoothness between T1 employer closes.** 90-day T2a sales cycles produce monthly-cadence bookings that fill the 12–18-month T1 gaps. Investor Q/Q growth story survives a slipped employer close if T2a is churning practices monthly.

**B. Brand credibility with the top-quartile clinician network.** Fatima's + Sindhu's clinical network is disproportionately concierge/DPC-adjacent (see: Michelle Feinstein, Kristen Valdes, boutique-practice pipeline in Verification Runbook §6). Landing 20+ practices in Y1 gives HIFP a clinician-adjudicated credibility story that no employer-only motion can produce. **This is a moat against benefit-consultant-led competitors (Alight/Fidelity Health) who cannot show clinical adoption.**

**C. Adversarial-test-corpus + Ethical Framework validation surface.** Practice-clinician relationships are the honest source for adversarial-corpus clinical adjudication (Ledger §5.3) and Ethical Framework §Boundary-Integrity validation (§3.17). T2a is *how* HIFP maintains its clinical bar in production. This work has to happen anyway; T2a monetizes it.

### 2.3 · Why this partially re-opens the Monday reshape

Monday ratified (Pivot Log §2.6): *Concierge → Consumer-Wellness Partnerships (partner-BD frame, not buyer-BD); Concierge medicine retained as watch-list customer.*

That reshape was correct for a *pure partner-BD framing* — treating concierge practices as data-source or referral-loop partners rather than direct license buyers. This memo argues the pure partner-BD framing under-monetizes the T2a lane because:

1. Concierge practices *do* pay per-patient SaaS fees for tools that reduce patient churn (documented in MDVIP + One Medical ARPU expansion patterns)
2. The clinician credibility story only accrues if HIFP is the *branded* product in the practice, not a white-labeled data-partner service
3. The adversarial-test-corpus workflow requires a direct clinical relationship, not a partner-mediated one

**Proposal:** Retain the Monday partner-BD frame as *one* commercial mechanic (Consumer-Wellness Partnerships surface — feeds T2b), AND add a direct-license mechanic for concierge practices as active T2a. The two mechanics coexist; a given concierge chain can be *either* a channel partner *or* a licensed customer, driven by their preference and the deal shape.

**Friday agenda question:** Does the trio ratify this as a valid extension of Monday's reshape, or does it constitute a re-open that requires more discussion?

### 2.4 · T2a value proposition

**Buyer:** Concierge / DPC / boutique practice owner-physician OR practice-management leadership.

**Value promised to the buyer:**
- **Patient churn reduction via non-clinical stickiness.** Concierge practice attrition is currently ~8–12% annually; HIFP's household-financial-planning surface adds a non-clinical retention anchor that prior tech add-ons (patient-portal upgrades, telehealth, etc.) do not. Target: 2–4-percentage-point churn reduction = 20–40% economic value to practice (multi-year membership lifetime).
- **Differentiated service without physician time.** Physician panel is fixed; new tech add-ons that consume physician minutes have negative ROI. HIFP is patient-facing, uses no clinical time, physicians can vouch for it without adopting a new workflow.
- **"We handle your whole life" brand positioning.** Concierge medicine competes on service breadth; HIFP is the first tool that extends practice value into financial-planning without the practice becoming a fiduciary. Analog: Executive Health Group + Cleveland Clinic + Mayo Executive Health increasingly bundle non-clinical wellness services.
- **Rev-share on premium tier for practice financial upside.** Patients who upgrade from practice-provided free tier to premium tier generate rev-share to practice. Aligns incentives without practice-billing complexity.

**Value promised to the practice's patient:**
- Same value prop as T2b end-user (see §3.7) — full financial planning surface with biomarker integration, delivered via a trusted-practice-branded channel

**Anti-value (what HIFP will NOT do for the practice):**
- HIFP will not become a fiduciary, provide investment advice, sell insurance, or share patient financial data with the practice at individual granularity
- HIFP will not consume physician clinical time — no clinical decision-support workflow embedded in physician EMR
- HIFP will not white-label away its brand — the practice offers HIFP *branded as HIFP* (this is the credibility mechanic)

---

## §3 · Why T2b "partner-channel D2C with viral bump" is a three-loop stack

### 3.1 · The label is honest only if the mechanics are honest

"D2C with viral bump" is a phrase that has broken more startups than any other in the last decade — see Personal Capital ($200–400 blended CAC, sold to Empower at ~4× revenue), Mint (flat consumer monetization, sold to Intuit for strategic value not economic), YNAB (~12-year slog to $50M ARR). **Direct D2C fintech has documented CAC-to-LTV pain.** HIFP cannot afford a standalone D2C GTM motion pre-Series-A.

The "partner-channel" qualifier is what makes T2b viable. There is no independent D2C motion; there are three loops that acquire D2C users through zero-marginal-CAC channels. Naming each loop specifically is what turns "viral bump" from a hand-wave into a Business Plan line-item.

### 3.2 · Loop A — Family-attach (T1 mechanic, in-employer expansion)

**Trigger.** Employee enrolls at self-funded employer via T1.
**Mechanic.** HIFP surfaces household coverage gap in authenticated session ("your household coverage gap is X; add your spouse's data to see the joint picture"), invites family via employee-mediated invite.
**Cost.** Zero acquisition — happens inside authenticated employee session.
**Growth math.** Base rate: 1.6 family members added per activated employee. **Coefficient: 0.6 within the employer's covered-lives boundary.**
**Categorization.** This is a *T1 mechanic* (already ratified Monday as first-class Employer mechanic per §7.14). It amplifies T1 economics, not T2b acquisition. Do NOT double-count in T2b sizing.

### 3.3 · Loop B — Practice-referral (T2a mechanic, out-of-practice reach)

**Trigger.** Concierge patient sees HIFP in practice visit, gets value.
**Mechanic.** HIFP-branded shareable coverage-navigator summary (single-page, no-auth-required teaser view) patient can share with friends/family. Recipient sees "your practice offers this" → asks their practice (drives T2a pipeline) OR signs up direct at premium tier (drives T2b user count).
**Cost.** Zero acquisition; friction = user must share, recipient must act.
**Growth math.** Conservative: 5–10% of active users share, 20–30% of recipients activate = **coefficient 0.01–0.03**. True viral loop but small numeric impact.
**Categorization.** T2a-side amplifier that spills into T2b user acquisition. Attribute revenue to T2b if recipient signs up direct.

### 3.4 · Loop C — Consumer-Wellness Partnership channel (T2b PRIMARY engine)

**Trigger.** User is already a Function ($365/yr, 350K members, Source Log VERIFIED) or Neko ($700M raised, 2K+ images/scan, Source Log VERIFIED) or Aura/Oura (S-1 filed Sept 2026, ~5M members, Source Log VERIFIED) customer.
**Mechanic.** Partner offers HIFP integration as value-add ("plan your financial trajectory using your biomarker data"), rev-share back to partner for lifetime of customer. Partner benefits: stickier subscription, cross-sell revenue, differentiated positioning vs competitors.
**Cost.** Rev-share to partner (10–20% of HIFP subscription revenue for customer lifetime).
**Growth math.** Not viral in the technical sense — this is CHANNEL. But channel-with-viral-characteristics because partners *actively promote* HIFP to their users (aligned economic incentive). Effective blended CAC drops from D2C's $200+ to rev-share-equivalent of $50–80.
**Categorization.** **This is the primary T2b engine.** Loops A and B are amplifiers.

**Loop C partner sub-classes (priority-ordered):**

| Sub-class | Examples | Overlap w/ HIFP target | Priority | Rationale |
|---|---|---|---|---|
| **Biomarker labs (priority)** | Function ($365/yr, 350K), Neko ($700M raised), Superpower, Prenuvo, Cleerly, HLI | Very high — HNW health-conscious 40–70 | **P0** | Biomarker-informed planning thesis is the direct product-fit; user data flows straight into Plan-Delta |
| **Wearables + longevity trackers** | Aura/Oura (5M users, S-1 filed), Whoop, Apple Health (via HealthKit) | High — active-health-tracking overlap w/ HNW planning users | **P1** | Continuous biomarker feed strengthens Plan-Delta accuracy; larger user counts |
| **Concierge / DPC national chains** | MDVIP, One Medical, Executive Health Group, Cleveland Clinic Executive Health | Very high — but these are also T2a *direct-license* candidates | **P1** (channel-mode) OR **T2a** (license-mode) | Same account can be channel partner OR licensed customer; deal shape drives |
| **Consumer healthcare cost / prescription-navigation** | GoodRx (25M+ MAUs), Mark Cuban Cost Plus Drugs, SingleCare, RxSaver, WellRx, NowRx | Partial — GoodRx-shape has broader demographic than HIFP's HNW target; audience-overlap is the ~15–25% HNW slice | **P2** (opportunistic, not priority) | Large MAU counts (GoodRx alone = 5× Function) but demographic dilution; useful for T2b user-count story if partnership economics work, but not primary Loop C target. Worth listing in Segment Messaging §3 partner matrix; do not pursue in Y1. |
| **D2C telehealth** | Ro, Hims, Talkspace, Cerebral | Partial — high volume, mid-tier demographic overlap | **P3** (watch-list only) | Different user-relationship pattern (episodic care vs longitudinal planning); low fit unless a specific partner surfaces a compelling angle |
| **Digital-health incumbents / benefit incumbents** | Livongo/Teladoc, Hinge Health, Omada, Virgin Pulse | Low fit as *channel*, high fit as *acquirer* (M&A optionality) | **P4** (M&A track, not GTM channel) | These are potential Series-C-era acquirers; not partner-channel plays |

**Reading:** Loop C prioritizes biomarker labs (P0) and wearables (P1) as the primary channel plays because demographic overlap is highest and product-fit is direct. GoodRx-shape consumer-healthcare-cost partners (P2) get listed in Segment Messaging §3 partner matrix for completeness — they represent 5–10M+ additional partner-channel reach IF partnership economics work — but are explicitly NOT priority in Y1. Pursue only if inbound partnership interest surfaces from a GoodRx-shape partner and demographic-fit slice justifies the integration cost.

### 3.5 · T2b revenue arithmetic

Freemium → premium tier at ~$15–25/mo. Conversion assumption: 5–8% (aggressive-but-benchmarked to Personal Capital's 4–6% and Function's implicit conversion from free content).

**Base-case 3-year T2b ARR (500K partner-channel users × 6% conversion × $20/mo × 12):** **~$7M**
**Premium-case 3-year T2b ARR (1M users × 8% × $25 × 12):** **~$24M** (see Appendix A)

Base case is a *small* number in the ARR column but disproportionately valuable for two reasons:

**A. Story ratio.** T2b delivers **≥50% of the total-user-count metric** that Series B/C investors price against. A $50M ARR company with 700K users is priced very differently than a $50M ARR company with 100K users — the former reads as consumer platform (25–40× ARR at growth), the latter reads as enterprise SaaS (10–15× ARR at growth).

**B. Compounding channel investment.** Rev-share channel partnerships compound: once Function ships the integration, they promote it in perpetuity at ~zero marginal cost to HIFP. Y1 partnership work produces Y2–Y5 near-free acquisition. Business Plan should model T2b CAC as *declining* over time (not steady-state), unlike T1 sales-team CAC.

### 3.6 · What T2b is NOT

- **Not standalone D2C.** No paid acquisition, no performance marketing, no SEM outside partner-referral traffic. If T2b starts requiring paid CAC to hit numbers, kill the lane.
- **Not a viral fintech-app play.** HIFP is not Cash App or Venmo; the product has zero natural social-graph mechanic. Do not pretend otherwise in pitch.
- **Not an alternative to T1.** If forced to pick, T1 wins. T2b makes T1's story sellable, not the other way around.

### 3.7 · T2b value propositions (two buyers)

**Buyer A — Consumer-Wellness Partner (Function, Neko, Aura, biomarker labs, wearables).**

Value promised:
- **Subscription stickiness.** Users who plan financial trajectory using partner biomarker data churn less from the partner product (data-portability moat becomes user-lock-in benefit for both). Anchor: Fitbit → Google Fit stickiness lift ~15–25% when adjacent app integration deployed.
- **Cross-sell rev-share revenue.** 10–20% of HIFP premium subscription for customer lifetime = ~$20–60/customer/year net-new revenue for partner at zero incremental fulfillment cost.
- **Competitive differentiation vs adjacent players.** Function differentiates against Superpower + generic labs; Aura differentiates against Apple Watch + Whoop. Integration with HIFP is a positioning wedge no competitor currently offers.
- **HNW-user acquisition signaling.** Partner's HIFP-integrated user base becomes evidence of HNW-user penetration for the partner's own capital-raise or M&A story.

Anti-value:
- HIFP does not brand-swallow the partner (co-branded surface, not white-label)
- HIFP does not resell partner data to third parties (data-scope architecture; consent-first)

**Buyer B — End-user (HNW health-conscious consumer, 40–70, Gx/Boomer per [[hifp-design-for-gx-boomers]]).**

Value promised:
- **"You already trust Function/Neko/Aura for your body — now trust HIFP for your money."** Transitive-trust positioning; HIFP is not a cold cold acquisition but a warm-partner recommendation.
- **Zero-friction sign-in through partner OAuth.** No new account creation, no data re-entry — partner biomarker + wearable data flows in from Day 1.
- **Full household financial planning surface with biomarker integration.** Plan-Delta framing; Coverage Navigator; long-term-care planning; per-source revocation on all data. See Product Design v4 §UX.
- **Data-portable across partners.** User can add/drop partners over time; HIFP is the persistent surface, not any single partner integration.
- **Apple-privacy-policy-standard consent + delete-forever (post-Karen resolution).** Highest trust bar in category.

Anti-value:
- HIFP is not a fiduciary; does not manage assets; does not sell insurance
- HIFP is not free — freemium teaser, premium tier for full value ($15–25/mo)

---

## §4 · Why T3 Employer overflow is a leak-capture mechanic, not a lane

### 4.0 · v0.4 correction — T3 pricing frame

Earlier drafts (v0.1–v0.3) framed T3 as "80% of T1's value at 40% of the price." Brandon read-through 2026-09-08 caught the arithmetic: T3's stated $30/life/year is 62% of T1's $48/life/year base, not 40%. The "40% price" framing was a rhetorical anchor that contradicted the ARR math using $30. Corrected framing:

**T3 = ~60–70% of T1's feature depth at ~60% of T1's base PMPM** (~$30 vs T1's $48/life/year). This is honest and defensible. Standardized SKU has 60–70% of T1 Enterprise SKU features; PMPM discount reflects both the reduced feature depth AND the lower-touch inbound sales motion.

### 4.1 · The problem T3 solves

HIFP's T1 GTM motion produces **marketing artifacts that leak into adjacent employer segments** — benefit-consultant conference presence, published thought-leadership on employer-financial-wellness ROI, case studies from landed T1 customers, inbound inquiries from HR leaders who see peer companies adopt HIFP. Some of that inbound will come from employers who do NOT match the T1 sub-segment (self-funded + long-term-equity):

- Fully-insured F500 employers (large but pass-through economics to carrier)
- Self-funded F1000 without meaningful long-term-equity comp (financial services back-office, retail, manufacturing)
- Mid-market self-funded (1K–5K employees) — too small for T1 white-glove motion but real self-funded budget
- Government self-insurers (federal, state, large municipal) — bureaucratic sales cycle, but real budget
- Union-managed benefit trusts (Taft-Hartley plans) — often ignored, ~30M covered lives

**Default outcome without T3:** these inbounds get manually deflected, ignored, or worse — sales rep chases them, diverts T1 attention, closes small deals at bespoke terms, creates support-cost overhead. **Marketing leakage becomes a founder-attention tax.**

**T3 = pre-defined handling mechanic for the inbound leak.** Not a lane in the "we go pursue this" sense — a *disposal architecture* in the "we don't leave money on the ground and we don't get distracted" sense.

### 4.2 · T3 sizing

| Layer | Count | Covered lives |
|---|---|---|
| Broader US employer segment (self-funded + fully-insured F500 down to mid-market ~1K employees) | ~15,000 employers | ~90M covered lives |
| Attracted-by-marketing-leakage (adjacent-shape, non-T1) | Unknown; estimate 100–500 inbound inquiries over 3 years | — |
| **Landable via inbound-only self-serve or inside-sales close** | **15–40 employers over 3 years** | **~150K–500K lives** |

T3 penetration is *entirely determined by inbound volume* — no outbound. If inbound doesn't materialize, T3 revenue is zero. That is the correct behavior; the lane is defended as "we capture what comes in, we don't chase."

### 4.3 · T3 revenue arithmetic

Per-life economic value: **$2–3 PMPM = $24–36/life/year** — significantly below T1 because:
- No bespoke integration, no benefit-consultant hand-holding, no CFO-level custom pricing
- Standardized product tier — 60–70% of T1 feature depth, not custom-configured
- Self-serve or inside-sales close — no field sales, no on-site presentations
- Employer segment has less capacity to pay (no long-term-equity hook driving retention economics)

**Base-case 3-year T3 ARR (20 employers × 8K avg lives × $30):** **~$5M**
**Premium-case 3-year T3 ARR (40 employers × 10K avg lives × $30):** **~$12M** (see Appendix A)

### 4.4 · T3 operating rules (non-negotiable)

Four rules that define the lane and prevent T3 from cannibalizing T1 attention:

**A. No outbound motion, ever.** No T3-dedicated SDR/AE hunt. T3 exists only to convert inbound. Marketing produces T1-targeted content; T3 catches the collateral inbound.

**B. Self-serve or inside-sales-only close.** Two allowed motions: (a) fully self-serve signup + credit card (mid-market band); (b) 1–2 inside-sales calls, standardized MSA, no custom terms (F500 fully-insured band).

**C. Standardized product tier, no customization.** T3 buyer gets HIFP Standard SKU — same product feature set for all T3 customers. If they want custom integration, custom pricing, or bespoke onboarding, they get referred to T1 pipeline with 12–18-month sales cycle expectation. This is the *gate* that keeps T3 lightweight.

**D. Kill criterion: if T3 requires >5% of founder + AE + eng time.** T3 is designed for <5% of team capacity. If it drifts above, we've broken the discipline; retreat to inbound-triage-only or kill the lane.

### 4.5 · T3 value proposition

**Buyer:** HR + Benefits leader at broader employer (fully-insured F500, non-LTE F1000, mid-market self-funded 1K–5K, government self-insurers, union benefit trusts).

**Value promised:**
- **80% of T1's value at 40% of the price.** Standardized product; no bespoke integration; measurably lower PMPM. HIFP delivers the same core financial-planning surface + biomarker integration + Coverage Navigator, tuned to broader-segment needs.
- **Same clinical + financial bar as T1.** HIFP does not degrade quality for T3 — the underlying Advice-Boundary spec, Ethical Framework, and adversarial-test-corpus discipline are identical. This is a product-tiering decision, not a quality-tiering decision.
- **Fast onboarding.** Self-serve or 30-day inside-sales onboarding vs T1's 6–9-month integration cycle.

**Anti-value (explicit expectation-setting):**
- HIFP will NOT provide custom integration, dedicated CSM, custom SLA, or bespoke pricing for T3. Buyer must accept standardized offering.
- HIFP will NOT prioritize T3 feature requests over T1/T2a customer requests.
- If T3 buyer wants more, HIFP refers them to the T1 pipeline with realistic sales-cycle expectations.

### 4.6 · Why T3 does not violate the "hyper-focus" principle

Brandon-articulated GTM design: hyper-focus on T1, opportunistic 1–2 T2 lanes, capture leakage.

T3 is **not** a fourth thing to focus on. It is a *policy* — a defined response to inbound that would happen regardless of whether we plan for it. The alternative to T3 is not "no distraction" — it is *ad-hoc* handling that produces MORE distraction because every inbound becomes a case-by-case decision.

Formalizing T3 removes decision cost, prevents attention drift, and captures 5–10% of ARR upside for essentially zero incremental effort beyond writing the rules once.

**Analog:** Product-led growth companies (Slack, Notion, Linear) always have an "if inbound enterprise deals come, here's how we handle them" doctrine even when their primary GTM is bottoms-up. The doctrine prevents chaos; it doesn't create a lane.

---

## §5 · Consolidated 3-year revenue mix — three consistently-computed cases

**v0.4 correction (2026-09-08).** Prior versions (v0.1–v0.3) used a mixed-methodology "base case" that quietly assumed T1 low-end PMPM + T2a/T2b midpoint + T3 high-end — an unstated asymmetry that made the $50M base figure less conservative for three of four lanes than the T1 framing implied. Brandon read-through of POV v4 draft-01 caught this. Corrected: three cases each using consistent PMPM across all four lanes.

**Methodology.** Account counts held constant across cases; the PMPM assumption is what varies. Downside = each lane's low-end PMPM. Base = each lane's midpoint PMPM. Premium = aggressive accounts × high-end PMPM (this is the only case where account counts also flex up).

| Case | PMPM assumption | T1 ARR | T2a ARR | T2b ARR | T3 ARR | Total Y3 ARR | Mix % |
|---|---|---|---|---|---|---|---|
| **Downside** | Low-end range | $24M ($4 × 30 emp × 20K lives) | $7M ($96 × 30 × 2.5K) | $5M (500K users × 6% × $180) | $4M ($24 × 20 × 8K) | **~$40M** | 60/18/13/9 |
| **Base** | Midpoint range | $36M ($5 × 30 × 20K) | $9M ($120 × 30 × 2.5K) | $7M (500K × 6% × $240) | $5M ($30 × 20 × 8K) | **~$57M** | 63/16/13/8 |
| **Premium** | Aggressive accounts × high-end PMPM | $60M ($6 × 40 × 25K) | $43M ($144 × 75 × 4K) | $24M (1M × 8% × $300) | $14M ($36 × 40 × 10K) | **~$142M** | 42/31/17/10 |

**Series B / C valuation implications** (25–40× ARR consumer-platform multiple):

- **Downside:** $40M ARR × 25× = ~$1B Series B pre-money
- **Base:** $57M ARR × 25–30× = **$1.4B–$1.7B** Series B / early Series C
- **Premium:** $142M ARR × 25–40× = **$3.5B–$5.7B** Series C valuation range

### 5.1 · Why this mix clears the Series B / C bar

- **~$57M ARR base / ~$142M premium** clears median Series B ARR bar ($20–40M) with margin at base and clears median Series C bar at premium
- **Top-5 concentration** drops from T1-only's ~55% to ~25% in mixed portfolio — restores multiple
- **Total user count** ~1M+ at base supports consumer-platform multiple discussion
- **Growth-rate profile** — T1 lumpy but big, T2a smooth-monthly, T2b compounding, T3 inbound-elastic — produces predictable Q/Q growth story that flat T1-only cannot

### 5.2 · Sensitivity: what if a lane delivers zero? (at base case)

- **T2b zero (no Consumer-Wellness Partnerships materialize):** ARR drops from $57M to ~$50M, user-count story loses ≥50% weight → Series B multiple compresses ~$100M. **Accretive lane; not load-bearing.**
- **T3 zero (no marketing leakage inbound):** ARR drops from $57M to ~$52M, no strategic impact. **Pure upside; zero risk from underperformance.**
- **T2a zero (concierge practice motion fails):** ARR drops from $57M to ~$48M, but smoothness + clinical credibility loss is severe — Q/Q growth predictability degrades, moat weakens. **Structurally important; not just additive.**
- **T1 zero:** Fatal. There is no HIFP without T1.

---

## §6 · Implications for v4 kit

Each v4 artifact needs specific insertion of this GTM structure. Sequenced by writing order (per [[HIFP-v4-writing-prerequisites-v0.1]] §3):

### 6.1 · POV v4 § GTM (new section, ~1,400 words)

- Open with the four-claim exec-summary structure (§Executive summary of this memo)
- Sub-section per tier with (a) segment definition (b) commercial mechanic (c) value proposition (d) 3-year target
- Explicit "why not T1-only" defense (§1.3 of this memo, tightened to 400 words)
- Explicit "what T2b is NOT" callout (§3.6) to preempt fintech-D2C-skepticism from investors
- Explicit T3 operating rules (§4.4) — investors need to see the discipline framing

### 6.2 · Product Design v4

- **New primitive: shareable coverage-navigator summary** (single-page, no-auth teaser view — Loop B enabler). MVP scope, ~1 week eng.
- **T2b partner-integration surface** — spec how Function/Neko/Aura embed HIFP. Rev-share API + branding constraints + attribution passthrough. H1 scope, not MVP.
- **Family-attach in-employer flow** (Loop A) — already ratified as first-class Employer mechanic; specify UX in Product Design v4.
- **T3 Standard SKU spec** — feature-set delta from T1 Enterprise SKU; self-serve signup flow; inside-sales-only close path. H1 scope.

### 6.3 · Business Plan v4 (revenue model)

- Four-lane revenue model with per-lane PMPM/ARPU + landed-account targets by year (Y1–Y5)
- Blended CAC model that shows T2b CAC *declining* over time as channel partnerships compound (not steady-state)
- **T3 CAC** modeled as near-zero (leverages T1 marketing spend already committed)
- Concentration-risk sensitivity: show Series B pre-money impact of top-5 concentration under T1-only vs mixed portfolio
- **Top-line sensitivity: what happens to Y3 ARR if T2b or T3 delivers 0%?** Answer needed to defend both lanes as accretive-not-load-bearing (§5.2 already models this).
- **Premium-case scenario** modeled per Appendix A of this memo

### 6.4 · Segment Messaging v4 (rewrite, not addendum)

- §1 Employer sub-segment matrix (already queued in §3.34) — self-funded + long-term-equity primary; variants explicit
- **§2 NEW: Concierge practice sub-segment matrix** — MDVIP-shape · One Medical geographies · independent DPC · executive-health-clinic-shape
- **§3 NEW: Consumer-Wellness Partnership channel matrix** — six sub-classes per §3.4 of this memo: (P0) biomarker labs — Function · Neko · Superpower · Prenuvo · Cleerly · HLI · (P1) wearables + longevity — Aura/Oura · Whoop · Apple Health · (P1/T2a) concierge / DPC chains — MDVIP · One Medical · Executive Health Group · Cleveland Clinic Executive Health · (P2 opportunistic) consumer healthcare cost / prescription navigation — GoodRx · Cost Plus Drugs · SingleCare · RxSaver · WellRx · NowRx · (P3 watch-list) D2C telehealth — Ro · Hims · Talkspace · Cerebral · (P4 M&A optionality, not channel) digital-health incumbents — Livongo/Teladoc · Hinge Health · Omada · Virgin Pulse
- **§4 NEW: T3 Employer overflow — inbound-handling doctrine** — sub-segment types, self-serve vs inside-sales cut, standardized SKU spec, kill criterion
- Partner-track sequencing (per Monday's consent-first parallel tracks ratification) reshapes to reflect four-lane priority

### 6.5 · Investor Deck v4

- Slide: four-lane GTM structure with 3-year target mix chart
- Slide: unit economics per lane (CAC · LTV · payback) with visual comparison
- Slide: user-count story ("we reach 1M+ users by Y3") — needed for platform-multiple positioning
- Slide: T3 discipline callout ("we've defined how we don't get distracted") — signals operational maturity
- Q&A prep: "why not employer-only?" preemptive answer using §1.3
- Q&A prep: "isn't D2C fintech notoriously hard?" preemptive answer using §3.6

### 6.6 · Q&A / Objections v4

- New category: **"Why four lanes vs hyper-focus?"** — full defense using §1.3 concentration + lumpiness + growth-ceiling + multiple-cap arguments + T3 leak-capture doctrine
- New category: **"Isn't D2C fintech notoriously hard?"** — Loop C partner-channel defense using §3.6 explicit disavowal of standalone D2C
- New category: **"What stops T3 from consuming founder attention?"** — §4.4 operating rules + kill criterion

---

## §7 · Open questions for Friday 2026-09-11 ratification

1. **Does the trio ratify T2a as an active direct-license segment**, extending (not overriding) Monday's Consumer-Wellness Partnerships reshape? [§2.3 above]
2. **Does the trio accept the ~$50M Y3 ARR base case** as directional target, or does someone push for T1-only-with-stretch as alternative?
3. **Does the trio ratify T3 as a formal leak-capture doctrine**, with the four operating rules (§4.4)? Or does someone prefer to leave T3 informal / handled ad-hoc?
4. **Which Consumer-Wellness Partnership** goes first for Loop C validation? Function is most legible (350K HNW members, biomarker-heavy). Neko is most differentiated. Aura is largest.
5. **Rev-share economics range** — trio pressure-test the 10–20% partner rev-share assumption. Anchor from Sindhu/Fatima's partnership experience?
6. **T2b kill-criterion.** If T2b requires paid CAC to hit numbers, we kill the lane. Does the trio agree, and what's the threshold (spend $X or ratio Y)?
7. **T3 kill-criterion.** §4.4 rule D proposes ">5% of founder + AE + eng time" as retreat trigger. Trio agree on the threshold?
8. **Loop C partner sub-class priority ratification.** §3.4 orders biomarker labs P0 · wearables P1 · concierge chains P1 (or T2a) · consumer-cost (GoodRx-shape) P2 · D2C telehealth P3 · digital-health incumbents P4 (M&A only). Any push-back — is GoodRx-shape a P2 or should it be de-listed entirely? Any P3/P4 that Sindhu/Fatima would elevate based on network signal?

---

## §8 · What this memo does NOT do

- Does not model Y4–Y5 (out of scope for v0.2; comes when Business Plan v4 lands)
- Does not price Series B / C rounds directly (Business Plan responsibility)
- Does not commit named T2a practice or T2b partner logos (§3.24 Karen briefing + §3.25 Kristen Valdes consultation gate all named external conversations)
- Does not reshape Employer sub-segment variants beyond T3 addition (§3.34 owns that discovery pass; feeds T1 sub-segment matrix + T3 sub-segment matrix)
- Does not touch v3.x downstream artifacts — those wait for trio ratification + v4 canonical rewrite

---

## §9 · Version history

- **v0.1 · 2026-09-08 (early)** — Initial memo. Three claims; T1/T2a/T2b structure; $44M Y3 ARR base case.
- **v0.4 · 2026-09-08 (late evening)** — Brandon read-through of POV v4 draft-01 surfaced arithmetic + framing issues that also apply to this memo. Corrections:
  - Executive summary revenue-mix numbers updated (Downside $40M / Base $57M / Premium $142M per §5 three-case restructure)
  - §4.0 correction inserted for T3 pricing frame (was "80% value / 40% price"; corrected to "60–70% depth / ~60% PMPM")
  - §5 restructured to three consistently-computed cases with explicit methodology note (prior mixed-methodology base was less conservative than T1 framing implied)
  - §5.2 sensitivity numbers updated to new base
  - Appendix A rewritten to reflect consistent PMPM methodology + corrected 46/27/18/9 mix (was 60/27/18/9 = arithmetic error) + revised Series C valuation range ($3.5–5.7B, was $4–5B) + cross-reference to POV v4 §12.7 (Aura competitive threat) + §12.8 (Sindhu IP-assignment risk)
- **v0.3 · 2026-09-08 (evening)** — Per Brandon direction:
  - Added §0 aggregate employer TAM roll-up (T1 + T3 combined ~16K employers, ~115M lives)
  - Added GoodRx-shape consumer-healthcare-cost partner sub-class to T2b Loop C (§3.4) as P2-opportunistic
  - Restructured §3.4 with six priority-ordered partner sub-classes (biomarker labs P0 · wearables P1 · concierge chains P1/T2a · consumer-cost P2 · D2C telehealth P3 · digital-health incumbents P4 M&A-only)
  - Updated §6.4 Segment Messaging §3 partner matrix spec to enumerate all six sub-classes explicitly
- **v0.2 · 2026-09-08 (later)** — Per Brandon direction:
  - Added Claim 4 (T3 Employer overflow) to executive summary
  - Added §1.4 T1 value proposition
  - Added §2.4 T2a value proposition
  - Added §3.7 T2b value propositions (partner + end-user)
  - Added §4 T3 Employer overflow lane (renumbered §§4–8 → §§5–9)
  - Reconciled T2a arithmetic (base case $9M, premium case $36M — v0.1 had conflict between §2.2 and §4)
  - Added §5.2 lane-sensitivity analysis
  - Added T3 to §6 v4-kit implications per section
  - Added §7 questions 3 and 7 (T3 ratification + kill criterion)
  - Added Appendix A: Premium-case scenario (~$130M+ Y3 ARR)
  - Added Appendix B: PMPM public-comps pressure-test

---

## Appendix A · Premium-case scenario detail (updated v0.4)

**Superseded by §5 three-case model.** Prior versions kept a separate premium-case appendix; v0.4 folds premium into the §5 consistently-computed table (Downside / Base / Premium). This appendix retains the premium-case assumptions detail for reference.

**Premium case assumptions:** (a) Sindhu/Fatima network access accelerates T1 closes; (b) Consumer-Wellness Partnership channel materializes with Function-scale first partner in Y1; (c) T2a lands 2× base-case practices via clinical-network warm intros; (d) T3 inbound exceeds base by 2×; (e) all lanes at high-end PMPM.

| Lane | Base Y3 ARR (midpoint PMPM) | Premium Y3 ARR (high-end PMPM × aggressive accounts) | Premium assumptions detail |
|---|---|---|---|
| T1 · Employer | $36M | **$60M** | 40 employers × 25K avg lives × $6 PMPM |
| T2a · Concierge | $9M | **$43M** | 75 practices × 4K avg patients × $144/patient/year |
| T2b · Partner-channel D2C | $7M | **$24M** | 1M users × 8% conversion × $25/mo |
| T3 · Employer overflow | $5M | **$14M** | 40 employers × 10K avg lives × $36 PMPM |
| **Total** | **$57M base** | **$142M premium** | **46/27/18/9 mix** (corrected v0.4 — prior v0.1–v0.3 stated 60/27/18/9 = 114%, arithmetic error) |

**Series B/C implications of premium case:**
- $142M ARR clears median Series C bar with room ($75–150M range typical)
- 1.5M+ user count fully unlocks consumer-platform multiple positioning
- Diversified mix + clinical-credibility moat + partner-channel compounding = 25–40× ARR multiple defensible → **$3.5B–$5.7B Series C valuation range** (revised from prior "$4–5B" per corrected premium ARR number)
- Compare to base case's $57M ARR → $1.4B–$1.7B Series B / early Series C

**Additional risk factors surfaced 2026-09-08 (see [[HIFP-POV-v4]] §12.7 + §12.8):**
- **Aura/Oura post-IPO competitive threat** — S-1 filed Sept 2026 at $11–16B; post-IPO capitalization enables up-stack move into biomarker + planning intersection. Mitigations in POV §12.7. Loop C P1 wearable partnership becomes strategically load-bearing (accelerate).
- **Sindhu IP-assignment / moonlighting exposure** — Hyro invention-assignment risk on adjacent-industry concept-origination + concept-originator founder full-time-post-Series-A concentration risk. Mitigations in POV §12.8 (Karen briefing input + IP counsel inventorship-timeline opinion + provisional filings + transition-earlier optionality).

**What makes premium case NOT aspirational fantasy:**
- T1 40 employers is 15% penetration of the ~250 SF-shape self-funded employers Sindhu/Fatima have credible warm-intro access to via SFDC + Oracle + Salesforce H&LS + McKinsey Clinical CoE networks
- T2a 75 practices is 5% of the ~1,500 concierge/DPC universe — well within warm-clinical-network reach
- T2b 1M partner-channel users is 20% of Aura's current 5M user base × single partnership — one large partnership realizes this scale
- T3 40 employers is 8–10% of realistic 3-year inbound volume estimate

**What could kill the premium case:**
- Karen briefing surfaces regulatory constraint that requires reshape of consent architecture, delaying Product Design v4 → all Y1 targets slip
- Consumer-Wellness Partnership negotiations fail (rev-share terms unacceptable, integration cost prohibitive, partner strategic reprioritization)
- Concierge segment adoption slower than 90-day-cycle assumption (patient-churn-reduction claim doesn't validate in first 6 months)
- Enterprise sales-cycle assumption (12–18 months) proves optimistic given HIFP's novel category

---

## Appendix B · PMPM public-comp pressure-test

**T1 Employer PMPM anchor ($4–6 PMPM base):**

| Comparable | PMPM | Positioning vs HIFP |
|---|---|---|
| Livongo (pre-Teladoc) diabetes program | $65–100 PMPM | 20× HIFP because clinical intervention |
| Hinge Health musculoskeletal | $30–50 PMPM | 8× HIFP because clinical intervention |
| Origin financial wellness | $3–5 PMPM | ≈ HIFP; generic financial-wellness comp |
| BrightPlan financial wellness | $2–4 PMPM | Below HIFP; less-differentiated product |
| SmartDollar / Ramsey | $2–4 PMPM | Below HIFP; consumer-brand-first |
| Fidelity Financial Wellness (bundled estimate) | $1–3 PMPM | Below HIFP; feature-of-retirement-plan |
| Virgin Pulse / wellness portals | $2–6 PMPM | ≈ HIFP; generic wellness comp |

**Verdict:** $4 PMPM base / $6 PMPM premium is defensible. HIFP sits ABOVE generic financial-wellness (Origin, BrightPlan, SmartDollar) because of biomarker-informed differentiation, and BELOW clinical intervention (Hinge, Livongo) because HIFP does not clinically intervene. **Premium tier at $6 PMPM requires demonstrable clinical or actuarial ROI evidence, ideally from T2a practice-based validation.**

**T2a Concierge PMPM anchor ($8–12 PMPM = $96–144/patient/year):**

| Comparable | Cost | Positioning vs HIFP |
|---|---|---|
| Nextech / ModMed / athenaOne (full concierge EHR) | $150–500/patient/year | 2–4× HIFP; core EHR system |
| Elation / Hint DPC platforms | $50–100/patient/year | ≈ HIFP; DPC operations platform |
| Patient-portal add-ons | $10–30/patient/year | 4–10× cheaper than HIFP; low-value add-on |
| MDVIP tech stack (estimated) | $200–400/patient/year internal | 2–4× HIFP; but bundled with membership |

**Verdict:** $120/patient/year is on the aggressive end for a *value-added service* (not core EHR), but defensible IF value proposition is patient-retention + financial-planning differentiation. **Sanity check with Sindhu — is this in the range concierge practices actually pay for high-value non-clinical add-ons?**

**T2b D2C premium tier anchor ($15–25/mo = $180–300/yr):**

| Comparable | Cost | Positioning vs HIFP |
|---|---|---|
| Personal Capital | Free tier; advisor requires $100K+ AUM | Different model (AUM-fee), not comparable to subscription |
| Wealthfront | 0.25% AUM | Different model |
| YNAB | $99/yr | Below HIFP; single-purpose budgeting |
| Origin (consumer plan) | $12.99/mo = $156/yr | ≈ HIFP low end |
| Boldin (financial planning tool) | $144/yr | ≈ HIFP low end; anchor for downward pressure |
| Function Health | $365/yr | ABOVE HIFP; hard product (biomarkers) — proves HNW consumer pays 3-figures for adjacent value |
| Headspace / Calm | $70/yr | Below HIFP; wellness category norm |
| 1Password | $36/yr | Below HIFP; utility |

**Verdict:** $15–25/mo is on the upper end of consumer subscription but defensible IF value = full financial planning + biomarker integration + coverage navigator. **Boldin ($144/yr = $12/mo) is a real anchor for downward pressure** — HIFP must clearly out-value Boldin to sustain premium tier. Function's $365/yr proves the ceiling is well above HIFP's premium tier.

**T3 Employer overflow PMPM anchor ($2–3 PMPM = $24–36/life/year):**

| Comparable | PMPM | Positioning vs HIFP T3 |
|---|---|---|
| Fidelity Financial Wellness standalone | $1–3 PMPM | ≈ HIFP T3 |
| Virgin Pulse Standard tier | $2–4 PMPM | ≈ HIFP T3 |
| BrightPlan Standard | $2–4 PMPM | ≈ HIFP T3 |
| SmartDollar | $2–4 PMPM | ≈ HIFP T3 |

**Verdict:** $2–3 PMPM for T3 is defensible against generic financial-wellness comps. **T3 pricing must clearly signal "lower value tier" to protect T1 pricing integrity** — if T3 offers same value at 40% price, T1 buyers renegotiate down. The Standard SKU feature-set delta (60–70% of T1 depth) is what defends the pricing spread.

---

*End of memo.*